A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. - Wikidata - awgldk - TriplyDB

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

http://www.wikidata.org/entity/Q34358819

about

Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation Gene aberrations for precision medicine against lung adenocarcinoma Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer Synthetic lethality in lung cancer and translation to clinical therapies SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition SMARCE1 regulates metastatic potential of breast cancer cells through the HIF1A/PTK2 pathway The disparate origins of ovarian cancers: pathogenesis and prevention strategies.CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer Systematic genomic and translational efficiency studies of uveal melanoma.Chromatin-regulating proteins as targets for cancer therapy.Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.Collateral Lethality: A new therapeutic strategy in oncology Carbon-ion beam irradiation kills X-ray-resistant p53-null cancer cells by inducing mitotic catastrophe Expression inactivation of SMARCA4 by microRNAs in lung tumors Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.Potential therapeutic targets in ARID1A-mutated cancers Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.SWI/SNF-Mediated Lineage Determination in Mesenchymal Stem Cells Confers Resistance to Osteoporosis.Mitotic catastrophe is a putative mechanism underlying the weak correlation between sensitivity to carbon ions and cisplatin.Mechanism of BRG1 silencing in primary cancers.CARMA: CARM1 methylation of SWI/SNF in breast cancer.

P2860

Q24320038-4BFD0412-BA85-4970-BFE4-D66073A74694 Q26749348-DC4222D2-603D-47B7-BC3E-374C09D9DC33 Q26863501-5AB083CF-C3E4-4708-B86B-70D8430AF8A4 Q27852975-CE8F6420-AE36-4647-9AB9-8E1496F39C34 Q27853293-52656077-AFD7-46DA-BF81-1DC02ABB063C Q28072904-7F5F6969-7B9F-4E03-A02C-C88C4EEAAD32 Q28818608-10637AE4-90E7-4347-9032-80D3826C75EA Q28829718-6B4BF02C-D848-41E4-A71C-65E0BB89C6AE Q28831292-D2CA87C8-E05A-4197-B05F-CB5BEDA6B1FA Q30240709-7D044594-DFFC-435C-B184-0AA93FB5FC72 Q33739791-ABAD88FE-3A82-481E-BC37-4D20E2A176CA Q33778295-E5318163-C460-4527-A5FF-8F220AD1D88A Q33907067-DC32B693-9527-4C6E-86E5-6730CAF0F008 Q34221658-BC330882-0600-4961-943E-D58BE4177FA1 Q34260197-DB48965C-5297-431D-B5C6-31568B6A825B Q34459131-D3FBE3C1-E98A-49F8-89C7-1911E599DDA8 Q34460151-53564847-8817-4C66-B315-D6AA3AF3214B Q34513800-F203FC11-BCEB-4346-BCD5-116622C4643D Q34756947-BE7B711C-1E76-4613-9DBB-C1140A597DED Q35063165-900C5588-712E-42BB-B9AA-C41A8E6F48AC Q35092542-837DC5A0-1508-4C9E-9E60-4828BBB71964 Q35096087-021376DB-CC51-4471-8C2A-5D7401378C2D Q35671373-4D5F2E50-0390-4BB0-84A9-07A17298FB46 Q35725518-7C381FAD-D508-4B6F-9A46-89AC989FE82A Q35797402-8EC913F8-0D4F-4BE3-A880-D6973789C3C2 Q36082984-AD7E627D-D257-4147-9FDA-6213F1D70E06 Q36169098-AEE7675F-37E3-4281-B085-15C0E192E0F0 Q36358757-69A5AEB7-DE4E-4790-B6CA-66C618154FA8 Q36420683-598A2E5D-14E4-440E-AEA8-CE8076D0A7C2 Q36558400-56F0B515-AFAC-4007-96A4-5BEEC2E2893F Q36584337-E99F1CD4-D0D4-4C8A-811A-90C504477B09 Q36584643-54C10026-5A54-4737-A270-1ADE623A4EA4 Q36738953-393D63EB-6DB1-45AE-A040-3CB9D1C2ABB2 Q36800071-490C4B98-A33D-4923-A3DE-664B47A3BFA2 Q37166723-A69E214E-5598-4ACB-9589-51031A29395B Q37225222-993627DC-FCB9-478F-A98D-E27275660894 Q37238318-903C30AA-1A3B-4119-AB40-A91822CB3CB8 Q37587579-4E2BF6C3-8E2A-452E-A280-FA39A418ACC2 Q37636601-3DEFFD04-B1CE-47D4-BE75-162B48DF938C Q37638142-3C89E970-92E7-4765-90CD-A7742F7BF6C8

P2860

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

http://www.wikidata.org/entity/Q34358819

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@ast

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@en

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@nl

type

label

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@ast

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@en

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@nl

prefLabel

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@ast

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@en

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@nl

P1433

Q34358819-B4D476D8-FA31-46EB-8E1E-A9D0BFE7C8CB

P1476

Q34358819-46E69017-A5B1-4B77-9321-71325A3A6DA5

P2093

Q34358819-16688C65-6E9A-4CAA-9297-67AE567AE77B

Q34358819-1C7A35F7-803A-4BCC-9F2C-CF9AB031016E

Q34358819-477F046D-8859-4BB9-8D9D-3916A2502E90

Q34358819-4DD33FF4-6E43-4605-81FF-B396C031B5A0

Q34358819-694EB593-BB86-4EE1-BEBD-13A1A36C7072

Q34358819-6D3FFC67-21F1-4C2A-9BF2-56523509E527

Q34358819-762BDB32-E047-4577-9570-2CB8F082C289

Q34358819-9516C210-454D-4ABA-B511-2A85D823F944

Q34358819-9C724A5D-3898-414C-BFC6-F4ACCF180624

Q34358819-A2922F71-56E5-4F01-8615-31372FD0DB08

P304

Q34358819-3AC7E08E-41D0-409F-92D0-2ACFE64C3E6A

P31

Q34358819-B0D24294-9E82-49AE-8A46-A7F5B2B7070A

P356

Q34358819-094C908B-4E38-474D-B3FB-62AE49BECC6F

P407

Q34358819-8C9E3426-44FF-4A68-8CF7-0048588D309A

P433

Q34358819-23194111-EA7C-4380-8C50-F9E4E8B51CB3

P478

Q34358819-9F8B5A37-D513-4E93-9C4A-E7E1CF2701E0

P577

Q34358819-233A71B0-343C-4F5A-B539-3024323895B5

P698

Q34358819-2672C31F-9368-479F-993C-B9B2FA4E7B6F

P356

0008-5472.CAN-12-4593

P1433

Cancer Research

P1476

A synthetic lethality-based st ...... omatin remodeling factor BRG1.

@en

P2093

Hideaki Ogiwara

http://www.w3.org/2001/XMLSchema#string

Hisanori Isomura

http://www.w3.org/2001/XMLSchema#string

Jun Yokota

http://www.w3.org/2001/XMLSchema#string

Kentaro Ito

http://www.w3.org/2001/XMLSchema#string

Koh Furuta

http://www.w3.org/2001/XMLSchema#string

Koji Tsuta

http://www.w3.org/2001/XMLSchema#string

Mayumi Komachi

http://www.w3.org/2001/XMLSchema#string

Osamu Ando

http://www.w3.org/2001/XMLSchema#string

Shun-Ichi Watanabe

http://www.w3.org/2001/XMLSchema#string

Takahiro Oike

http://www.w3.org/2001/XMLSchema#string

P304

5508-5518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-12-4593

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23872584

http://www.w3.org/2001/XMLSchema#string